Histamine H2 receptor antagonist-refractory oesophagitis: The efficacy of long-term omeprazole maintenance treatment

Italian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 6, 1997, Pages 515-519

  Bardhan, K D ^a   Cherian, P ^a   Jones, R B ^a   Vaishnavi, A ^a   Manek, S ^a   Bishop, A ^a   Polak, J ^a   Brooks, A ^a   Morris, P ^a   Thompson, M ^a   D'Silva, J ^a   Parkin, S ^a   Patterson, J ^a   Gillon, K R W ^a  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

Histamine H2 receptor antagonists; Maintenance therapy; Omeprazole; Refractory erosive oesophagitis

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; RANITIDINE; ENZYME INHIBITOR; GASTRIN;

ARTICLE; CLINICAL ARTICLE; DRUG MEGADOSE; ESOPHAGITIS; FEMALE; HEALING; HUMAN; MAINTENANCE THERAPY; MALE; REMISSION; ADULT; AGED; BIOPSY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; ESOPHAGUS; FOLLOW UP; GASTROSCOPY; HYPERPLASIA; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; REFLUX ESOPHAGITIS; SECRETION; STOMACH MUCOSA; TREATMENT OUTCOME; WOUND HEALING;

ADULT; AGED; BIOPSY; CIMETIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTRINS; GASTROSCOPY; HISTAMINE H2 ANTAGONISTS; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; OMEPRAZOLE; RANITIDINE; RECURRENCE; TREATMENT OUTCOME; WOUND HEALING;

EID: 0031282949     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bardhan KD, Morris P, Thompson M, Dhande DS, Hinchliffe RFC, Jones RB, et al. Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. Gut 1990;31:745-9.
2. Maratka Z. Terminology definitions and diagnostic criteria in digestive endoscopy. Scand J Gastroenterol 1984;19(Suppl. 103):27.
3. Facer P, Bishop AE, Lloyd RV, Wilson BS, Hennessy RJ, Polak JM. Chromogranin: a newly organised marker for endocrine cells of the human gastrointestinal tract. Gastroenterology 1985:89:1366-73.
4. Grimelius L. A silver nitrate stain for A2 cells in human pancreatic islets. Acta Soc Med Uppsal 1968:73:243-70.
5. Sevier AC, Munger BC. A silver method for paraffin section of neural tissue. J Neuropath Exp Neurol 1965:24:130-5.
6. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayal AD, Falkmer S, et al. Histopathological classification of non antral gastric endocrine growths in man. Digestion 1988;41:185-200.
7. Bryant MG, Adrian TE. Gastrin. In: Bloom SR, Long RG, editors. Radioimmunoassay of gut regulatory peptides. London: WB Saunders, 1982:51-9.
8. Lundell L. Prevention of relapse of reflux oesophagitis after endoscopie healing. The efficacy and safety of omeprazole compared with ranitidine. Digestion 1990;47(Suppl. l):72-5.
9. Clissold SP, Campoli-Richards DM. Omeprazole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986:32:15-47.
10. Bürget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers. Gastroenterology 1990;99:345-51.
11. Bell NJV, Bürget D, Howden CW, Wilkinson J, Hunt RH. Ap-propriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992;51(Suppl. l):59-67.
12. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993;7(SuppI. 1): 13-24.
13. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sei 1991;36:552-7.
14. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Medl994;121:161-7.
15. Bank S, Magier D, Greenberg R, Blunstein M. Alternate day omeprazole maintenance therapy in FhRA resistant esophagitis clinical, gastrin and ECL effects for up to 3 years. Gastroenterology 1992;102:A35.
16. Bank S, Greenberg R, Blunstein M, Magier D, Schulman N, Brigante L. "Spaced" omeprazole dosing in maintenance therapy of HiRA resistant reflux esophagitis - results from 6 to 48 months. Gastroenterology 1993;104:A38.
17. Bardhan KD, Daly MJ, Jones RB, Singh S, Morris P, Thompson M, et al. Refractory erosive esophagitis maintenance treatment with high dose H2 receptor antagonists or omeprazole. World Congress of Gastroenterology, Sydney, Australia. 26-31 August 1990. Abstract Book 1, page 56.
18. Savarino V, Mêla GS, Zentilin P, Cutela P, Mêle MR, Perilli D, et al. Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. Dig Dis Sei 1994;39:1473-82.
19. Brunner GHG, Lamberts R, Creutzfeldt W. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 1990;47(SuppI. l):64-8.
20. Klinkenberg-Knol EC, Meuwissen SGM. Treatment of reflux oesophagitis resistant to Hi-receptor antagonists. Digestion 1989;44(Suppl. l):47-53.
21. Koop H, Hotz J, Pommer G, Klein M, Arnold R. Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to Hi-receptor antagonists. Aliment Pharmacol Ther 1990;4:593-9.
22. Zeitoun P, Diebold MD, Richardson S, Duchateau A, Bigard MA, Colin R, et al. Density of fundic ECL cells during long term treatment of reflux esophagitis by omeprazole or histamine Hi-receptor antagonists. Gastroenterology 1995;108:A266.